In a webinar organized by the Hong Kong Association for the Study of Liver Diseases (HKASLD), Professor Kim, Seung-Up and Dr. Wong, Yu-Jun Eugene introduced the new paradigms in viral hepatitis disease control. While Prof. Kim discussed some topics of hepatitis B virus (HBV) management, including the increased risk of kidney disease with long-term antiviral use and the appropriate first-line agents to mitigate this risk, Dr. Wong presented the challenges of hepatitis C virus (HCV) management and access to care, highlighting the efficacy and safety of the direct-acting antiviral (DAA) treatment of sofosbuvir/ velpatasvir (SOF/VEL) in HCV patients and the simplified treatment monitoring in reducing the healthcare burden.

Glossary: DAA: Direct-acting antiviral; HCV: Hepatitis C virus; RNA: Ribonucleic acid; SoC: Standard of care; SOL/VEL: Sofosbuvir/velpatasvir; SVR: Sustained virologic response; the US: The United States

Glossary: aRR: Adjusted rate ratio; CI: Confidence interval; HCC: Hematocellular carcinoma; HCV: Hepatitis C virus

Glossary: BC: Breast cancer; HCV: Hepatitis C virus; IDU: Injection drug user; LFU: Lost to follow-up; OR: Odds ratio; RNA: Ribonucleic acid; SVR: Sustained virologic response

Glossary: DAA: Direct-acting antiviral; DDI: Drug-drug interaction; GLE/PIB: Glecaprevir/Pibrentasvir; HCV: Hepatitis C virus; PWID: People who inject drug; SOF/VEL: Sofosbuvir/velpatasvir

Glossary: Ab: Antibody; GOP: General out-patient; HCC: Hematocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; PWID: People who inject drug; RNA: Ribonucleic acid; SOF/VEL: Sofosbuvir/velpatasvir